Thrivent Financial for Lutherans
RLAY icon

Thrivent Financial for Lutherans’s Relay Therapeutics RLAY Stock Holding History

Thrivent Financial for Lutherans’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-87,418
Closed -$456K – 2637
2025
Q3 		$456K Sell
87,418
-79,250
-48% -$302K ﹤0.01% 2111
2025
Q2 		$576K Hold
166,668
– – ﹤0.01% 2078
2025
Q1 		$436K Hold
166,668
– – ﹤0.01% 2125
2024
Q4 		$687K Buy
166,668
+6,210
+4% +$33.8K ﹤0.01% 2110
2024
Q3 		$1.14M Buy
160,458
+40,447
+34% +$302K ﹤0.01% 1827
2024
Q2 		$782K Buy
+120,011
New +$820K ﹤0.01% 1999

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thrivent Financial for Lutherans's RLAY Position: Q4 2025 in Review

Thrivent Financial for Lutherans sold out of Relay Therapeutics (RLAY) in Q4 2025, closing a stake of 87,418 shares — an estimated $456K sold.

Thrivent Financial for Lutherans first reported a position in RLAY in Q2 2024 and held it in 6 quarters. The position peaked at $1.14M in Q3 2024. 227 funds tracked by Wall St. Rank hold RLAY as of Q4 2025.

  • Thrivent Financial for Lutherans reported no remaining Relay Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 87,418 Relay Therapeutics shares in Q4 2025, an estimated $456K.
  • Thrivent Financial for Lutherans first reported a position in Relay Therapeutics in Q2 2024 and held it in 6 quarters.
  • Thrivent Financial for Lutherans's Relay Therapeutics position peaked at $1.14M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2025, filed 5 Feb 2026.